[ad_1]
BERGEN, Norway, March 18, 2019 / PRNewswire / – Cytovation AS, a private biotechnology company, announces that the first patients have been treated in a Phase I clinical study with CyPep-1, a new therapeutic agent being developed as a new topical warts therapy induced by HPV. The launch of this clinical trial marks the beginning of the clinical development of CyPep-1 for dermatology and oncology applications, with a CyPep-1 phase I trial in malignant tumors scheduled for the second half of 2019.
CyPep-1 was designed and developed by Cytovation. It is a first clbad lytic agent with wide application on benign and malignant tumors due to its new mechanism of action. CyPep-1 selectively targets tumor cells, forming pores that destabilize and break the membrane to kill the cell and release neo-antigens into the microenvironment and circulation, while leaving healthy cells intact. The release of neo-antigens allows CD8-positive cytotoxic T cells to develop a systemic immune response offering the possibility of lasting immunity against the tumor and, in the case of warts, an HPV infection. For more information on the action mode, click here.
Cytovation has formulated CyPep-1 as a cream for the topical treatment of HPV-induced warts, an important medical need for which there is currently no approved drug treatment. The company has also developed CyPep-1 as a solution for intratumoral injection, either alone or in combination with checkpoint inhibitors.
Scientific Director of Cytovation, Lars Prestegarden, I said: "We are very happy to take this first clinical step with CyPep-1 and begin its official clinical development. We designed CyPep-1 to exploit the key differences between healthy cells and tumor cells and found strong evidence of its efficacy in preclinical tumor models. We are eager to see if these results can be translated to humans with both this new test on warts and the future test on cancer. Both tests should begin in 2019 and we look forward to the first results later in the year."
The CyPep-1 clinical trial is a double-blind, randomized, placebo-controlled Phase I study. The study is conducted at the Center for Research on Drugs for Human Use (Leiden, the Netherlands). the Netherlands) and will recruit 58 patients with cutaneous warts. Results are expected by the end of 2019. (ClinicalTrials.gov ID: NCT03846648)
Notes to editors:
About Cytovation
Cytovation AS is a privately held biotechnology company developing CyPep-1, a first-clbad lytic agent, as a new immunotherapy for benign and malignant tumors. Visit www.cytovation.com for more information.
About HPV Induced Warts
Warts are benign tumors of the skin caused by the human papillomavirus (HPV). There are more than 100 strains of HPV that can cause several types of warts (common, flat, plantar, bad). Warts are highly contagious and affect up to 12% of the population and up to 20% of children. The removal of warts is traditionally done by skin abrasion, cutting, freezing or other over-the-counter products, but there is no curative treatment and recurrence is common. There is a significant medical need and a superior business opportunity $ 4 billion per year for safe and effective treatment that eliminates warts and cures HPV infection.
SOURCE Cytovation AS
Related Links
https://www.cytovation.com/
Source link
